Globally, about 1% of pregnant women are persistently infected with the hepatitis C virus (HCV) 1 . Mother-to-child transmission of HCV occurs in 3-5% of pregnancies 2 and accounts for most new childhood infections 1, 3 . HCV-specific CD8 + cytotoxic T lymphocytes (CTLs) are vital in the clearance of acute HCV infections [4] [5] [6] , but in the 60-80% of infections that persist, these cells become functionally exhausted or select for mutant viruses that escape T cell recognition [7] [8] [9] . Increased HCV replication during pregnancy 10, 11 suggests that maternofetal immune tolerance mechanisms 12 may further impair HCVspecific CTLs, limiting their selective pressure on persistent viruses. To assess this possibility, we characterized circulating viral quasispecies during and after consecutive pregnancies in two women. This revealed a loss of some escape mutations in HLA class I epitopes during pregnancy that was associated with emergence of more fit viruses 13 . CTL selective pressure was reimposed after childbirth, at which point escape mutations in these epitopes again predominated in the quasispecies and viral load dropped sharply 14 . Importantly, the viruses transmitted perinatally were those with enhanced fitness due to reversion of escape mutations. Our findings indicate that the immunoregulatory changes of pregnancy reduce CTL selective pressure on HCV class I epitopes, thereby facilitating vertical transmission of viruses with optimized replicative fitness.
Globally, about 1% of pregnant women are persistently infected with the hepatitis C virus (HCV) 1 . Mother-to-child transmission of HCV occurs in 3-5% of pregnancies 2 and accounts for most new childhood infections 1, 3 . HCV-specific CD8 + cytotoxic T lymphocytes (CTLs) are vital in the clearance of acute HCV infections [4] [5] [6] , but in the 60-80% of infections that persist, these cells become functionally exhausted or select for mutant viruses that escape T cell recognition [7] [8] [9] . Increased HCV replication during pregnancy 10, 11 suggests that maternofetal immune tolerance mechanisms 12 may further impair HCVspecific CTLs, limiting their selective pressure on persistent viruses. To assess this possibility, we characterized circulating viral quasispecies during and after consecutive pregnancies in two women. This revealed a loss of some escape mutations in HLA class I epitopes during pregnancy that was associated with emergence of more fit viruses 13 . CTL selective pressure was reimposed after childbirth, at which point escape mutations in these epitopes again predominated in the quasispecies and viral load dropped sharply 14 . Importantly, the viruses transmitted perinatally were those with enhanced fitness due to reversion of escape mutations. Our findings indicate that the immunoregulatory changes of pregnancy reduce CTL selective pressure on HCV class I epitopes, thereby facilitating vertical transmission of viruses with optimized replicative fitness.
The first woman (subject M001) whom we tracked through two pregnancies had a history of chronic genotype 2b HCV infection (additional patient details are available in the Online Methods). Viremia was nearly 1 × 10 6 IU ml −1 at study enrollment during the third trimester of the initial pregnancy, fell 10,000-fold after delivery and remained low (<1 × 10 4 IU ml −1 ) through a 26-month interpregnancy period (Fig. 1a) . Viral levels rebounded to 1 × 10 6 IU ml −1 during the second pregnancy before again dropping 10,000-fold following delivery and becoming undetectable 17 months later. Neither pregnancy resulted in vertical transmission of HCV. Clonal sequencing of circulating viral genomes revealed a total of 13 amino acid substitutions after the first pregnancy and additional substitutions during the second pregnancy and postpartum period (Fig. 1b) . A close phylogenetic relationship of the HCV genomes over time was consistent with viral evolution within this subject rather than superinfection (Supplementary Fig. 1 ).
Large swings in viremia and nonsynonymous evolution of the HCV genome through consecutive pregnancies could be indicators of changing CTL selective pressure against epitopes and perhaps altered viral fitness for replication 7, 13, 15 . Of the nonsynonymous mutations detected after the first pregnancy, only R495T was situated in a previously described HLA class I epitope 16 (Fig. 1b,c) . Expansion of a peripheral blood CTL line specific for the B*5101-restricted epitope spanning amino acids 492-500 (YPPRPCGIV, designated 492/9) confirmed recognition of this epitope in M001 (Fig 1d) . The viral R495T substitution at position 4 of the epitope (YPPTPCGIV) conferred escape from the CTL response, but, surprisingly, this R495T immune escape substitution reverted to wild-type sequence during the second pregnancy and was then replaced by a unique CTL escape substitution, R495K, after delivery ( Fig. 1b-d) . This gain-loss-gain pattern of substitution was not seen elsewhere in the viral genome. We tested the three variants observed at position 495 before, during and after the second pregnancy for their impact on replication of the cell culture-adapted genotype 2a virus JFHxJ6 17 . The R495T substitution did not affect RNA replication when compared with the Arg495 wild-type sequence (Fig. 1e) , but it considerably impaired production of infectious virus (Fig. 1f) . Position 495 is highly conserved (arginine or lysine) in genotypes 1-6 and appears critical for viral entry on the basis of alanine substitutions in HCV-pseudotyped lentiviruses 18, 19 . The conservative R495K substitution that emerged after the second pregnancy had no effect on infectious virus production ( Fig. 1f) but Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses enabled escape from the CTL response (Fig. 1d) . Clearance of viremia 17 months after the second delivery was associated with emergence of a 492/9 CTL response cross-reactive to this R495K mutant (Fig. 1d) .
A second subject (M003) presented with jaundice at week 26 of pregnancy with apparent acute HCV genotype 1a infection. Jaundice and elevated alanine aminotransferase (ALT) levels resolved in the final weeks of the first pregnancy, whereas viremia climbed to greater than 1 × 10 7 IU ml −1 (Fig. 2a) . A transient 1,000-fold decline in viremia and spikes in ALT followed the first delivery. Viremia remained elevated through the second pregnancy and again transiently fell 1,000-fold after delivery. Genetic sequences of the dominant viral quasispecies were stable during the last 6 weeks of the first pregnancy but rapidly evolved after delivery of the first child (Fig. 2b) . Of 13 amino acid substitutions observed at week 25 postpartum, eight occurred within described or predicted HLA class I epitopes and diminished T cell recognition by postpartum peripheral blood mononuclear cells (PBMCs), CTL lines npg or both (data not shown). Two of these substitutions, L1403F and K2471R, transitioned through the same gain-loss-gain pattern of mutation observed for the 492/9 epitope in subject M001, and we therefore evaluated them for their impact on T cell recognition and HCV replication. The L1403F substitution was located in the overlap of two welldescribed HLA-B*0801-restricted epitopes in the viral NS3 protein (1395/9 HSKKKCDEL and 1402/9 ELAAGKLVAL, the common Leu1403 residue is underlined) 20 (Fig. 3a) . L1403F allowed more efficient escape from postpartum 1395/9 and 1402/9 CTL lines when antigen was delivered to target cells by mRNA transfection than when it was supplied as exogenous peptide, which indicates that L1403F probably disrupted processing of these epitopes for class I presentation 20 (Fig. 3b) . L1403F was dominant in the viral quasispecies circulating in M003 from 25 weeks after the first delivery until the start of the second pregnancy (Fig. 3a) . Nevertheless, a transition to wildtype sequence began by the second trimester of the second pregnancy, reaching more than 95% of sequenced clones by the third trimester. Interestingly, the wild-type Leu1403 that arose midway through the second pregnancy was encoded by a new codon, TTG, rather than the conventional CTC codon found at other time points, suggesting de novo selection of the wild-type leucine variant in pregnancy (Supplementary Fig. 2 ). Later synonymous replacement of the TTG codon by CTC suggests selective codon usage bias, possibly owing to constraints on secondary RNA structure or to the abundance of complementary IAG tRNA anticodons in the human liver 21 . Twelve weeks after delivery, the L1403F substitution began to reappear in association with detectable 1395/9 and 1402/9 interferon-γ (IFN-γ) T cell responses in the blood (Fig. 3c) , but it was soon replaced by unique escape substitutions (K1398R and A1409T) within the separate HLA-B*0801 epitopes that eliminated peptide recognition (Fig. 3a,b) . Incorporation of L1403F into the H77S.3 (ref. 22 ) cell culture-adapted virus (genotype 1a) had little impact on viral RNA replication. Infectious virus yields were only 20% those of wild-type virus, however (Fig. 3d,e) , suggesting that L1403F may interfere with NS3/4A function during virus assembly 23 . The later K1398R plus A1409T substitutions similarly reduced infectious virus production but also appeared somewhat detrimental for RNA replication (Fig. 3d,e) , perhaps because Lys1398 is located within the helicase RNA-binding motif IV 13 .
The second reverting substitution in M003, K2471R, was located at position 6 of the HLA-B*1501-restricted epitope 2466/9 (SQRQKKVTF) 24 in the NS5B protein and was accompanied by substitutions at position 2 within the same epitope ( Fig. 4a and  Supplementary Fig. 3 ). The predominant 2466/9 variant to emerge after the first pregnancy (and 12 weeks after the second pregnancy) was the double mutant Q2467K/K2471R (SKRQKRVTF). This variant demonstrated complete escape from an M003-derived 2466/9 specific CTL line (Fig. 4b) . Late in the second pregnancy, the K2471R substitution at position 6 reverted to wild type, whereas position 2 switched to a common Q2467L polymorphism found in 16% of curated genotype 1a viruses 25 . Reversion of K2471R in the context of Q2467L (SLRQKKVTF) substantially restored recognition by the 2466/9 CTL line, although not to the degree of the original wild-type epitope (Fig. 4b) . The 2466/9 epitope was in close proximity to another HLA-B*1501-restricted epitope, designated 2450/9, that acquired a stable T cell escape substitution at position 3 (H2453Y) after the first delivery (Fig. 4a,b) . Incorporation of the postpartum escape mutations from both B*1501 epitopes (H2453Y/Q2467K/K2471R in Fig. 4c ) into the H77S.3/GLuc2A system impaired viral replication, as determined by secreted luciferase activity 22 . Virus with the sequence found at the second delivery (H2453Y/Q2467L in Fig. 4c ) replicated as well as virus with the original wild-type sequence, despite the residual H2453Y escape mutation in the 2450/9 epitope. These data indicate first that in npg pregnancy the quasispecies at 2466/9 shifted from an effective CTL escape sequence to one optimized for viral replication. Second, the equivalent replication of virus with His2453 (wild-type) as compared to that with Tyr2453 (2450/9 escape mutant) ( Fig. 4c) is consistent with the notion that the CTL escape mutations that were stable through pregnancy were less detrimental to viral replication than reverting substitutions or were balanced by compensatory mutations 26 . Nevertheless, we cannot exclude the possibility that enhanced virus replication during pregnancy due to loss of some escape mutations is at least partially offset by the other more stable substitutions in the HCV genome. Until now, very few HCV strains have been adapted for replication in cell culture. Assessing the collective impact of all mutations present during and after pregnancy in a native viral backbone must await development of a more robust cell culture model that facilitates replication of primary HCV strains such as those isolated from subjects M001 and M003. Both infants (C003 and D003) born to M003 were negative for HCV RNA at birth but positive for HCV RNA upon subsequent testing at 19 and 12 weeks of age, respectively, indicating perinatal or late intrauterine viral transmission 27 (Fig. 2a) . Viruses sequenced from C003 at week 25 and D003 at week 12 closely approximated those present in maternal plasma at delivery (Fig. 2b) . Viral sequences from D003 contained each of the class I escape mutations that were stable in M003, but not the NS3 or the NS5B mutations that had transiently reverted to wild type during the second pregnancy ( Supplementary  Figs. 2 and 3) . C003 inherited the maternal HLA-B*0801 class I allele and D003 inherited the HLA-B*1501 allele, but in both children the 1395/9, 1402/8 and 2466/9 epitopes remained unchanged through more than a year of follow-up (data not shown). Transmission of more fit wild-type or revertant viruses could conceivably favor a persistent course of infection in infants, particularly if they lack the restricting maternal class I allele 28 or if they fail to exert effective and timely CTL pressure on targetable HCV epitopes, as suggested by the absence of evolution of the B*0801 epitopes in C003 and the B*1501 epitope in D003. Additional studies that address the kinetics and effectiveness of acute-phase CTL responses of perinatally infected infants and consider inheritance patterns of maternal and paternal class I alleles are needed to understand the role of infant CTL responses in HCV evolution and protection from persistence.
The phenomenon of 'reversion' of unfit CTL escape mutations has been previously described after viral transmission to recipients lacking the restricting HLA allele and has been inferred from HLA-virus sequence polymorphism studies 24, 29, 30 . Observed reversion of three escape mutations in four epitopes targeted by subjects M001 and M003 provides, to the best of our knowledge, the first examples of this phenomenon within individuals with established chronic hepatitis C. As a surrogate readout of in vivo intrahepatic HCV-specific CTL activity, this evolution of viral class I epitopes suggests, first, that intrahepatic CTLs exert a degree of ongoing selective pressure on epitopes before pregnancy and, second, that these CTLs may be inhibited by the immunoregulatory changes of pregnancy. Collectively, our findings suggest that the increase in viremia often observed during pregnancy 10, 11 is related to relaxed HCV-specific CTL immunity, coupled perhaps with increased replicative fitness of the virus. Increases in replication during pregnancy are important, as some studies have linked high maternal viral loads, particularly >1 × 10 7 IU ml −1 as seen in subject M003, with an increased risk of vertical transmission 2, 31 . It is noteworthy that numerous known immunoregulatory changes of pregnancy parallel those found in chronic HCV infection and could conceivably exacerbate HCV-specific CTL dysfunction in pregnancy, including expansion of T regulatory cells 32 and enhanced expression of immunosuppressive molecules such as negative costimulatory ligands and receptors 33, 34 , HLA-G 35, 36 and indoleamine 2,3-dioxygenase 37, 38 .
Postpartum reacquisition of escape mutations coincident with detectable IFN-γ responses in the peripheral blood in M003 indicates that CTLs targeting these epitopes regain efficacy and probably contribute to the coincident declines in viremia that often follow delivery 14 . Although function may be restored to CTLs targeting revertant epitopes in the postpartum period, it remains unknown whether the same is true of T cells that target persistently intact epitopes. Outside of pregnancy, chronic-phase CTLs targeting intact epitopes are phenotypically distinct from 39 and may be more profoundly exhausted than 8 those targeting escaped epitopes. Study of this highly unusual postpartum revival of HCV-specific cellular immunity could provide unique insight into mechanisms of T cell silencing and interventions to restore function in the chronic phase of infection. Such mechanisms are likely to be relevant to other persistent viruses, such as HIV and, particularly, hepatitis B virus, where viral load dynamics during and after pregnancy parallel those of HCV 40 . Finally, our data indicate that relaxation of cellular immunity and emergence of viruses that lack key escape mutations in the pregnant mother may result in vertical transmission of HCV variants with enhanced fitness for replication. Together, these findings highlight the fine balance between replicative npg fitness and evasion of host immunity that shapes HCV quasispecies, and they suggest that a systemic reduction of cellular immunity during pregnancy provides a unique niche for reemergence of fit virus variants with consequences for both mother and child.
MeTHODS
Methods and any associated references are available in the online version of the paper.
Accession numbers: Viral genomic sequence data from subjects M001, M003, C003 and D003 are available in GenBank via accession codes JQ061323 through JQ062389.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ONLINe MeTHODS
Subjects. HCV-infected subjects M001 and M003 were recruited from The Ohio State University Substance Treatment, Education and Prevention in Pregnancy (STEPP) program, a clinic that provides prenatal care and addiction treatment services for pregnant women with substance abuse histories. Followup visits for mothers and their infants were accomplished at Nationwide Children's Hospital. Approval for this study was provided by institutional review boards at the Ohio State University and Nationwide Children's Hospital, and informed consent was obtained for all subjects. Subject M001 was enrolled at the age of 26 years in the thirty-fifth gestational week of pregnancy. She had HCV genotype 2b viremia and a reported history of persistent HCV infection for more than 5 years. Both of her pregnancies were delivered at term by cesarean section due to prior cesarean section. Subject M003 presented at the age of 34 years in the twenty-sixth gestational week of pregnancy with jaundice, elevated alanine aminotransferase (ALT) levels and HCV genotype 1a viremia. Her symptoms were attributed to acute HCV infection on the basis of a reported needle stick in the first trimester of pregnancy, a negative HCV serologic test 18 months before she presented and exclusion of other infectious and non-infectious causes of acute hepatitis. She received two doses of betamethasone at 31 weeks' gestation to promote fetal lung maturity and delivered infant C003 vaginally at 34 weeks' gestation. No corticosteroids were given during her second pregnancy, and she delivered infant D003 vaginally at 38 weeks' gestation. Generation of HCV-specific CD8 + T cell lines from peripheral blood. T cell lines specific for class I epitopes 492/9 (YPPRPCGIV) in subject M001 and 1395/9 (HSKKKCDEL) and 1402/9 (ELAGKLVAL) in subject M003 were derived by antigen stimulation of cryopreserved postpartum peripheral blood mononuclear cell (PBMC) samples. Briefly, 2 × 10 6 -6 × 10 6 thawed PBMCs were resuspended in 2 ml RP10-IL2 medium (RPMI 1640, 10% FCS and penicillin/streptomycin) with recombinant interleukin-2 (IL-2, 50 U ml −1 ) in a 24-well plate and stimulated with the respective peptide at a final concentration of 10 µg ml −1 . Fresh RP10-IL-2 medium was added every 3-4 d. After 11-16 d, CD4 + cells were depleted (Dynabeads; Invitrogen), and remaining cells were stimulated with mouse anti-human CD3 antibody (Beckman Coulter, clone X35, final concentration 0.015 µg ml −1 ) and irradiated heterologous feeder PBMCs. After 3-4 weeks in culture, the epitope specificity of each cell line was determined by IFN-γ intracellular cytokine staining (ICS) or ELISPOT assay. In some cases, CTL lines were subcloned to derive lines with greater epitope specificity. Class I HLA restriction was confirmed using peptide-pulsed partially HLA-matched heterologous B lymphoblastic cell lines (BLCLs) in the IFN-γ ICS assay.
Viral sequence analysis.
IFN-g ELISPOT assay.
The affinity of CTL lines for wild-type versus mutant epitopes was tested by a titration of the respective peptides in the IFN-γ ELISPOT assay. IFN-γ-producing CD8 + T cells were enumerated with the IFN-γ ELISPOT (U-CyTech) after a 42-h stimulation with peptide (wildtype or variant) and autologous irradiated BLCLs in duplicate as previously described 15 . Direct IFN-γ ELISPOT assays of fresh or frozen PBMCs using peptide pools or individual peptides were performed without additional antigen-presenting cells.
Intracellular cytokine stain assay. CD8 + T cell lines were stimulated with either peptide-pulsed or HCV mRNA-transfected autologous BLCLs with mouse anti-human CD28 (BD Pharmingen, clone CD82.2, final concentration 1 µg ml −1 ) and mouse anti-human CD49d (BD Pharmingen, clone 9F10, final concentration 1 µg ml −1 ) co-stimulation as previously described 15 . GolgiPlug (BD Biosciences) was added after 1 h of incubation. After 16 h, cells were stained for CD8, CD4, CD3, intracellular IFN-γ and vitality and were analyzed on a Becton Dickinson LSRII flow cytometer as previously described 15 . Antibodies used were as follows: mouse anti-human CD3 (peridinin chlorophyll protein conjugated; BioLegend, clone UCHT1, final concentration 4 µg ml −1 ), mouse anti-human CD4 (Pacific Blue conjugated; BioLegend, clone OKT4, final concentration 1.25 µg ml −1 ), mouse anti-human CD8 (allophycocyanin conjugated; BioLegend, clone RPA-T8, final concentration 1 µg ml −1 ) mouse antihuman IFN-γ (phycoerythrin conjugated; BD Pharmingen, clone 4S.B3, final concentration 1 µg ml −1 ) and Live/Dead Green (Molecular Probes, 1:1,000).
HCV mRNA transfection of BLCLs. Peptides bearing the initial L1403F substitution did not escape recognition by M003 1395/9 or 1402/9 T cell lines as efficiently as peptides bearing the separate K1398R and A1409T substitutions when tested by IFN-γ ICS (Fig. 3b) , leading us to hypothesize that the L1403F mutation might escape the M003 CTL responses more by disrupting intracellular epitope processing than by impairing T-cell receptor recognition 20, 48 . To test the effect of intracellular antigen processing, we adapted the method described by Timm et al. 20 to transfect HCV mRNA variants bearing these epitopes into autologous antigen-presenting cells. Briefly, representative NS3 viral sequence clones from week −6 (wild-type), week 40 (L1403F), and week 152 (K1398R/A1409T) were used as template for a third-round PCR that would be used to generate the mRNA. The forward primer included a T7 promoter with the Kozak consensus sequence and M003 nucleotides 3947-3963 (5′-TAATACGACTCACTATAGGGAGAGCCACCATGGACGAGTGCCAC TCCACG-3′). The reverse primer included a stop codon, coding sequence for
